← Back to headlines
Guardant Health Receives Landmark FDA Approval for Companion Diagnostic Test
The U.S. Food and Drug Administration has granted approval for Guardant Health's Guardant360 CDx test to be used alongside AstraZeneca's camizestrant for treating advanced breast cancer patients.
4 Sept, 22:10 — 4 Sept, 22:10
